Genomics England Improved Scale and Performance for On-Premises Cluster
NeuralMesh™ by WEKA® allows Genomics England (GEL) to scale to extreme performance and capacity in their mandate to sequence 5 million genomes by 2023. GEL, headquartered in London, is owned by the UK Department of Health and Social Care to run the 5 million genomes project, announced in 2018, which aims to sequence 5 million genomes from National Health Service (NHS) patients with rare diseases.
Download the case study to learn how Genomics England achieved 10X+ higher performance and reduced storage costs per genome by 75% with NeuralMesh™.
Download Now